Published in Blood Weekly, July 8th, 2004
"We performed a prospective observational study to assess the safety of stopping maintenance therapy for disseminated histoplasmosis among HIV-infected patients after response to antiretroviral therapy. All subjects received at least 12 months of antifungal therapy and 6 months of antiretroviral therapy before entry," wrote investigators at Indiana University.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.